Collectively, our findings suggest that HDAC11 interacts with the IRF4/BLIMP1/MYC transcriptional network (24), which is critically dysregulated in myeloma genesis, and HDAC11 inhibition offers a potential therapeutic strategy for MM treatment. This evidence concerns the gene IRF4 and Miyoshi myopathy.